A polymer of the formula/structure wherein R represents alkyl, alkoxy, aryl, or heteroaryl; each R1 and R2 is independently hydrogen (H), a suitable hydrocarbon; a heteroatom containing group or a halo...
|7485733||Organic compounds for electroluminescence and organic electroluminescent devices using the same|
Disclosed is a novel group of compounds having a general structure of anthracene body substituted with at least one thiophenyl group, which can be further substituted with various substituent groups. These new compounds are generally compatible with organic electrol...
|7462725||Chloromethylation of thiophene|
The process according to the invention relates to the preparation of 2-chloromethyl-thiophene of the formula (I). During this process thiophene is chloromethylated in the presence of one or more compounds containing keto group and optionally it is transformed into t...
|7459567||Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators|
The present invention provides a substituted thienyl or furyl acylguanidine compound of formula I The present invention also provides methods for the inhibition of β-secretase (BACE) and for the treatment of β-amyloid dep...
A compound having a structure is disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed. ...
|7432289||5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors|
Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. ...
Disclosed herein are compounds of the formula or salts or bioisosteres thereof. Therapeutic methods, medicaments, and compositions related thereto are also disclosed. ...
|7423061||Substitute thiophenes and uses thereof|
This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer. ...
The invention relates to novel substituted thiene-3-ylsulphonylamino(thio)carbonyl-triazolin(ethi)ones of the formula (I) in which Q1, Q2, R1, R2, R3...
|7411093||Aminocycloalkanes as DPP-IV inhibitors|
The present invention relates to compounds of formula (I) wherein R1 is as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or p...
|7396943||Opioid receptor antagonists|
A compound of the formula I: (I) wherein the variables are as described herein, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture thereof, formulations and methods of use thereof are disclosed.
|7393865||Sleep inducing compounds and methods relating thereto|
Compounds having the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts, esters and solvates thereof, wherein R1, R2, R3a, R3b, L
|7388118||Amine 1,2- and 1,3-diol compounds|
Disclosed are compounds of formula: and pharmaceutically acceptable salts and esters thereof, useful in treating and/or preventing Alzheimer's disease and other similar diseases, wherein RN, RC, R...
This invention relates to novel methylthiophenecarboxanilides of the formula (I) in which R1, R2, R3, R4, R5 and R6
|7371503||Sulfonium salt compound, photoacid generator, and positive-tone radiation-sensitive resin composition|
A sulfonium salt compound excelling in transparency to deep ultraviolet rays at a wavelength of 220 nm or less, exhibiting well-balanced excellent performance such as sensitivity, resolution, pattern form, LER, and storage stability when used as a photoacid generato...
|7329686||Substituted thiophene compounds|
There are provided novel compounds of formula (I) wherein R1, R2, R3, R10, M, Q, T, U, Y, V and W are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their prepara...
|7319111||Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists|
The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use. ...
|7316851||Electroluminescent material, electroluminescent element and color conversion filter|
An electroluminescent element is disclosed, comprising an electroluminescent material and a fluorescent substance emitting light having an emission maximum at the wavelength different from that of light emitted from the electroluminescent material upon absorption of...
|7300951||Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof|
Compounds of Formula (I), are provided where T is CHO, CON, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substit...
The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in ...
Acene-thiophene compounds are disclosed that are useful as organic semiconductors. The compounds, when used as the semiconductor layer in organic thin-film transistors exhibit device characteristics, like charge-carrier mobilities and current on/off ratios, that are...
|7256923||Switchable window based on electrochromic polymers|
Syntheses of a new blue EC monomer (ProDOT-MePro), and a new red EC monomer (ProDOP-Et2) are described. Two additional new types of EC monomers based on 3,4-alkylenedioxythiophene include fluorinated EC monomers and an EC monomer including silicon. EC polymer device...
|7241776||Cyanoamidine P2Xantagonists for the treatment of pain|
Novel cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R1-R12 are as defined in the specification act as antagonists of the P2X7 receptor. These compo...
Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. ...
|7214805||Process for the industrial synthesis of strontium ranelate and its hydrates|
The process for the industrial The synthesis of strontium ranelate of formula (I): and its hydrates. ...
|7173060||Oxime derivatives and their use as pharmaceutically active agents|
The present invention relates to compounds of formula I, their pharmaceutically acceptable salts as well as their enantiomeric forms, diastereoisomers and racemates; the preparation of the above-mentioned compoun...
|7135579||Dibenzothiophene oxide compound, and process for producing the same|
There are disclosed novel compounds, liquid crystal compositions, polymers, optically anisotropic producgs, and optical or liquid crystal elements that have large refractive index anisotropy, mix easily with other liquid crystals, have advantageous stability against...
|7125428||1,3-Dihydroxybenzene derivatives and colorants containing said compounds|
1,3-Dihydroxybenzene derivatives of general formula (I) or (Ia) or physiologically tolerated, water-soluble salts thereof wherein R′1 denotes a substituted pyridyl group, a pyrimidyl group, a group of formula (...
|7122626||Halogen-substitued thienyl compounds|
Halogen substituted thienyl compounds exhibit potential as nucleic acid (especially double stranded DNA) binders and as antibiotic compounds. A representative thienyl compound has the structure ...
|7115755||Reactive mesogenic azulenes|
The invention relates to new reactive mesogenic azulene derivatives, their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like for example liquid crystal displays, optical films, organic field effect transistor...
|7109354||Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions|
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I
|7105683||Process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates|
The process for the industrial the synthesis of the compound of formula (I): Application to the the synthesis of bivalent salts of ranelic acid and more especially strontium ranelate and its hydrates. ...
|7094515||Stimulus sensitive compound and stimulus sensitive composition containing the same|
A stimulus sensitive composition containing a compound capable of generating an acid or a radical on receipt of an external stimulus, the compound being represented by the following formula (I): wherein Y represe...
|7081467||C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals|
The present invention is directed C2-disubstituted indan-1-ones of the Formula I, physiologically acceptable salts, and physiologically functional derivatives thereof, and pharmaceutical compositions comprising s...
|7078465||Process to bromomethylate aromatic compounds|
The present invention provides a process for bromomethylation of organic compounds, wherein said process is a two stage process comprising of the following stages: a) reacting paraformaldehyde with hydrogen bromide and separating bis-bromomethyl ether (BBME) from th...
Disclosed herein are compounds of formula II: wherein Alk, Z, X1, X2, R1, —R10 and R11 are defined herein, and their salts and pharmaceutically acceptable deriva...
|7052742||Five membered-ring compounds and utilization thereof in liquid crystal mixtures|
Fluorinated five-membered ring compounds of the formula (I) R1—X—(A1—M1)a—(A2—M2)b—A3—Y—E (I) where E is a radical T—Z—R2
|7053228||Sulfur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids|
The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and/or prophylaxis of disease associated to an excess of glucocorticoids. In particular, the invention relates to the...
|7038828||Electrochromic organic polymer synthesis and devices utilizing electrochromic organic polymers|
Large contrast ratio and rapid switching laminated electrochromic (EC) polymer device includes transparent electrode, cathodic EC polymer, gel electrolyte, and counter-electrode. Preferably the cathodic EC polymer is a poly(3,4-propylenedioxythiophene) derivative, P...
|7037927||Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor|
The present invention relates to compounds of formula (I) that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity. ...